.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Colorcon
Express Scripts
Federal Trade Commission
US Department of Justice
Julphar
QuintilesIMS
Teva
Baxter
McKesson

Generated: June 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202595

« Back to Dashboard
NDA 202595 describes OSELTAMIVIR PHOSPHATE, which is a drug marketed by Nesher Pharms, Amneal Pharms, and Natco Pharma Ltd, and is included in three NDAs. It is available from five suppliers. Additional details are available on the OSELTAMIVIR PHOSPHATE profile page.

The generic ingredient in OSELTAMIVIR PHOSPHATE is oseltamivir phosphate. There are seven drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the oseltamivir phosphate profile page.

Summary for NDA: 202595

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 202595

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
OSELTAMIVIR PHOSPHATE
oseltamivir phosphate
CAPSULE;ORAL 202595 ANDA Alvogen Inc. 47781-468 47781-468-13 1 BLISTER PACK in 1 CARTON (47781-468-13) > 10 CAPSULE in 1 BLISTER PACK
OSELTAMIVIR PHOSPHATE
oseltamivir phosphate
CAPSULE;ORAL 202595 ANDA Alvogen Inc. 47781-469 47781-469-13 1 BLISTER PACK in 1 CARTON (47781-469-13) > 10 CAPSULE in 1 BLISTER PACK

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 30MG BASE
Approval Date:Aug 3, 2016TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 45MG BASE
Approval Date:Aug 3, 2016TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 75MG BASE
Approval Date:Aug 3, 2016TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Harvard Business School
Chinese Patent Office
Moodys
Johnson and Johnson
Deloitte
Cantor Fitzgerald
Cerilliant
Fuji
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot